Top 20 Companies in the Global BCG Tuberculosis (TB) Vaccine Market: Industry Intelligence Report by Spherical Insights (2024–2035)
RELEASE DATE: Mar 2026 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Description
According to a research report published by Spherical Insights & Consulting, the Global BCG Tuberculosis (TB) Vaccine Market Size is projected to grow from USD 62.4 Million in 2024 to USD 98.11 Million by 2035, at a CAGR of 4.2% during the forecast period 2025–2035. Global market expansion is fuelled by a surge in tuberculosis (TB) cases, and the simultaneous growth in awareness of TB and vaccination programs initiatives.
Introduction
TB remains a major global health issue which results in millions of new cases every year. The World Health Organisation reported that 8.3 million new TB cases were notified worldwide in 2024. In addition, low- and middle-income countries that have inefficient healthcare facilities in treating TB cases still face the challenge of TB despite the advancements in healthcare. This is because factors such as poverty and poor nutrition, in addition to HIV infection, weaken the immune system and make one susceptible to TB infection. In 2024, about 5.8% of the world cases of tuberculosis occurred in the context of HIV people. People all over the world are now taking health measures as they learn about how to prevent diseases. People have come to realize that vaccination prevents infectious diseases such as TB because they have improved their health literacy. The greater the awareness of the tuberculosis threat and accompanying the mitigation of such threat through proper use of the BCG vaccine, the more there's going to be demand when it comes to BCG vaccines. The WHO/UNICEF 2024 estimates show that more than 85% of the world population receives the BCG vaccine, but different regions show different vaccination rates, especially in areas with low income.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the BCG Tuberculosis (TB) Vaccine Market.
BCG Tuberculosis (TB) Vaccine Market Size & Statistics
- The Market Size for the BCG Tuberculosis (TB) Vaccine Was Estimated to be worth USD 62.4 Million in 2024.
- The Market Size is Going to Expand at a CAGR of 4.2% between 2025 and 2035.
- The Global BCG Tuberculosis (TB) Vaccine Market Size is anticipated to reach USD 98.11 Million by 2035.
- Asia-Pacific is estimated to dominate the market during the forecast period in the BCG Tuberculosis (TB) Vaccine Market.
- Latin America is projected to grow the fastest during the forecast period in the BCG Tuberculosis (TB) Vaccine Market.
Market Segmentation
Global BCG Tuberculosis (TB) Vaccine Market Size, Share, By Type (Immune BCG and Therapy BCG), By Application (Hospitals and Clinics), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035.
Regional growth and demand
Asia-Pacific is expected to dominate the market during the forecast period in the BCG tuberculosis (TB) vaccine market.
Asia-Pacific held the majority of the market share by revenue for the BCG tuberculosis (TB) vaccine market. The countries such as India, China, Indonesia and the Philippines maintain their TB vaccination dominance through their substantial TB disease burden, their large population size and their widespread neonatal vaccination campaigns and their robust government vaccination programs. The region experiences increased BCG vaccine demand because of these factors, which drive greater vaccination rates than other areas.
Latin America is projected to grow the fastest during the forecast period in the BCG tuberculosis (TB) vaccine market.
Latin America is projected to grow the fastest during the forecast period in the BCG Tuberculosis (TB) vaccine market. The region experiences growth through its implementation of neonatal BCG vaccination programs, which operate universally and through increased public awareness about TB prevention, and through the consistent occurrence of TB cases in both urban and rural areas. Brazil, Mexico and Argentina together propel this market expansion because their governments implement programs that boost vaccination rates through their improved vaccine distribution systems and their health awareness initiatives.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the BCG Tuberculosis (TB) Vaccine Market.
Ready to lead the BCG Tuberculosis (TB) Vaccine Market?
Discover the regional trends and growth factors shaping the industry. We’re here to assist with expert, personalized data.
Call +1 303 800 4326 or Send us a message for a personalized consultation.
Top 10 Trends in the BCG Tuberculosis (TB) Vaccine Market
- Rising global burden of tuberculosis driving demand
- Expansion of national immunization programs
- Advancements in vaccine R&D and formulation improvements
- Development of nextgeneration/recombinant BCG vaccines
- Paediatrics segment dominance with growing birth cohorts
- Growth of adult and specialrisk immunization applications
- Public procurement and government funding emphasis
- Bladder cancer therapeutic applications supporting market expansion
- Supply capacity expansion and manufacturing investments
- Regional market growth disparities and emerging market focus
1. The global burden of tuberculosis is creating a growing need for medical services
The BCG vaccine sees persistent strong demand because TB cases remain high throughout low- and middle-income countries. The vaccine maintains its status as the primary protective solution against diseases that endanger both children and vulnerable groups.
2. Expansion of national immunization programs
High-burden regions see their governments expand neonatal vaccination programs, which lead to increased BCG vaccination throughout their areas. Public health initiatives serve as the primary method to achieve TB prevalence reduction.
3. Advancements in vaccine R&D and formulation improvements
Researchers are currently developing BCG vaccine improvements that enhance both effectiveness, security and distribution systems. The current research works on developing advanced freeze-dried products and developing storage methods that provide better stability.
4. Development of next generation/recombinant BCG vaccines
The new BCG strains that scientists create through engineering work aim to establish superior and prolonged protective immunity. The upcoming vaccines will provide solutions to tackle TB among adult patients and people who possess diminished immune strength.
5. Paediatrics segment dominance with growing birth cohorts
BCG vaccination remains most common among children who live in Asia-Pacific regions, which experience increasing birth rates. Neonatal immunisation programs serve as the essential foundation for international TB prevention efforts.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the BCG Tuberculosis (TB) Vaccine Market.
Empower your strategic planning
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the anti-venom market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Top 20 Companies Leading the BCG Tuberculosis (TB) Vaccine Market
- Merck & Co., Inc.
- Sanofi Pasteur
- Serum Institute of India Pvt. Ltd.
- Japan BCG Laboratory
- China National Pharmaceutical Group (Sinopharm)
- Statens Serum Institute (SSI)
- Bio Farma (PT Bio Farma)
- GreenSignal Bio Pharma Limited
- InterVax Ltd.
- Microgen (NPO Microgen)
- AJ Vaccines A/S
- Biomed Lublin S.A. (Synthaverse S.A.)
- Taj Pharmaceuticals Limited
- Biological E. Limited
- Haffkine BioPharmaceutical Corporation Ltd.
- Indian Immunologicals Limited
- Panacea Biotec Ltd.
- Lupin Limited
- BBNCIPD Ltd.
- Valneva SE
1. Merck & Co.
Headquarters: Rahway, New Jersey, United States
Merck & Co., Inc. started its operations in 1891 and today functions as a leading American pharmaceutical company that produces vaccines. Merck achieved its financial results for 2024 through various revenue sources, including its vaccine products, which brought in substantial income, yet the company did not share specific revenue figures linked to BCG products. The company offers a diverse range of products, which include vaccines, BCG and oncology medications and treatments for infectious diseases and products for animal health. It provides services to customers in North America, Europe, Asia-Pacific, and Latin America.
2. Sanofi Pasteur
Headquarters: Paris, France
Sanofi Pasteur operates as the vaccine division of Sanofi S.A., which started its operations in 1973. In 2024, Sanofi reported revenues of approximately USD 48.1 billion across its global healthcare operations, including vaccines, pharmaceuticals, and biologics. Sanofi Pasteur’s vaccine collection contains numerous vaccines, which include BCG for tuberculosis and vaccines for influenza, meningitis and other infectious diseases, and its products reach markets in more than 100 countries throughout the world. The company leads vaccination initiatives worldwide by developing vaccines that serve both industrialised and emerging economies
3. Serum Institute of India Pvt. Ltd
Headquarters: Pune, India
Serum Institute of India Pvt. Ltd. The Serum Institute of India started its operations in 1966 in Pune, India and has developed into the largest vaccine producer worldwide, which supplies vaccines to immunisation programs that operate in more than 170 nations. The institute produces various vaccines, which include BCG for tuberculosis and polio, DTP and Hib and other vaccines.
4. Japan BCG Laboratory
Headquarters: Tokyo, Japan
The Japan BCG Laboratory started operations in 1952, and it specialises in manufacturing BCG (Bacillus CalmetteGuérin) vaccines of superior quality. The laboratory has supplied freeze-dried BCG strain (Tokyo 172), which serves tuberculosis prevention purposes for more than 50 countries, exporting over 2 billion doses. The company operates as one of the top specialist manufacturers within the worldwide BCG supply chain because its main operations focus on producing BCG vaccines together with other biological products.
5. China National Pharmaceutical Group
Headquarters: Beijing, China
China National Pharmaceutical Group Corporation (Sinopharm) was founded in 1998. The state-owned pharmaceutical company operates as one of China’s largest pharmaceutical conglomerates, and its 2024 revenue reached approximately USD 80.1 billion because the company manages various pharmaceutical and vaccine operations together with healthcare product development activities. Sinopharm operates a global network, which enables the company to export its products and take part in international immunisation programs while providing vaccines and therapeutics to customers worldwide. The company operates across multiple continents, which include Asia and Africa and Europe and Latin America.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the BCG Tuberculosis (TB) Vaccine Market.
Are you ready to discover more about the BCG Tuberculosis (TB) Vaccine Market?
The report provides an in-depth analysis of the leading companies operating in the global BCG tuberculosis (TB) vaccine market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardised format that includes:
Company Profile
- Merck & Co., Inc.
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
- Sanofi Pasteur
- Serum Institute of India Pvt. Ltd.
- Japan BCG Laboratory
- China National Pharmaceutical Group (Sinopharm)
- Statens Serum Institute (SSI)
- Bio Farma (PT Bio Farma)
- GreenSignal Bio Pharma Limited
- InterVax Ltd.
- Microgen (NPO Microgen)
- AJ Vaccines A/S
- Biomed Lublin S.A. (Synthaverse S.A.)
- Taj Pharmaceuticals Limited
- Biological E. Limited
- Haffkine BioPharmaceutical Corporation Ltd.
- Indian Immunologicals Limited
- Panacea Biotec Ltd.
- Lupin Limited
- BBNCIPD Ltd.
- Valneva SE
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the BCG Tuberculosis (TB) Vaccine Market.
Conclusion
The global BCG tuberculosis (TB) vaccine market size is expected to grow at a compound annual growth rate (CAGR) of 4.2%, from USD 62.4 Million in 2024 to USD 98.11 Million by 2035. Global market expansion is fuelled by a surge in tuberculosis (TB) cases, and the simultaneous growth in awareness of TB and vaccination programs initiatives. Asia-Pacific is expected to dominate the market during the forecast period due to its consistent TB vaccination dominance through its substantial TB disease burden, its large population size, its widespread neonatal vaccination campaigns and its robust government vaccination programs. Latin America is projected to grow the fastest during the forecast period in the BCG Tuberculosis (TB) vaccine market. The region experiences growth through its implementation of neonatal BCG vaccination programs, which operate universally and through increased public awareness about TB prevention, and through the consistent occurrence of TB cases in both urban and rural areas.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?